Session Details

Tuesday Posters - Bipolar Disorder

Tuesday, 10 February 2004 16:00 -17:00

Hall 5, Exhibition Halls

Posters will be on display from Tuesday, 10 February until Thursday, 12 February.

Presenters will be in attendance to discuss their posters in this topic between 16:00-17:00 on Tuesday, 10 February.

The effects of first-degree family history of schizophrenia on bipolar mania
  • Kuo-Hsuan Chung, Taipei City Psychiatric Center, Taipei, Taiwan
    • Burden of Manic vs Depressive Symptoms in Subjects with Bipolar Disorder
  • Dr Mark Frye, University of California at Los Angeles, United States
    • Providing care to adolescents with bipolar disorder difficulties at reaching an early diagnosis and compliance to therapy
  • Raquel Zamora, CAPTA, Uruguay
    • Peripheral biological markers in psychotic and nonpsychotic subtypes of mania
  • Marina Sagud, Clinical Hospital Center Rebro, Zagreb, Croatia
    • Pharmacokinetic interaction and tolerability of lamotrigine and olanzapine co-administration in healthy volunteers
  • Dr Gary Evoniuk, GlaxoSmithKline, United States
    • Safety and tolerability of lamotrigine in bipolar I disorder
  • Dr Eduard Vieta, University of Barcelona, Spain
    • Effects of lithium and lamotrigine prophylaxis on body weight in patients with bipolar I disorder
  • Dr Charles Bowden, University of Texas Health Science Center - San Antonio, United States
    • Open-label use of lamotrigine maintenance treatment in bipolar depression: Combination therapy experience
  • Dr Philip Mitchell, University Of New South Wales, Australia
    • Concomitant use of Lamotrigine with lithium or Valproate in bipolar I disorder
  • Dr Charles Bowden, University of Texas Health Science Center - San Antonio, United States
    • The effects of lithium and lamotrigine in prevention of relapse/recurrence of bipolar I depression
  • Dr Lakshmi Yatham, University of British Columbia, Canada
    • Lamotrigine controls bipolar depression without destabilizing mood
  • Dr Michael Berk, University of Melbourne, Australia
    • Lamotrigine and lithium as maintenance treatment for bipolar I disorder
  • Dr Lakshmi Yatham, University of British Columbia, Canada
    • Olanzapine in combination with Valproate or lithium in the treatment of maniac patients: An open study
  • Professor;MD Mesut Cetin, GATA Hyadarpasa Training Hospital, Turkey
    • Quetiapine monotherapy for the treatment of mania
  • Martin Brecher, AstraZeneca, United States
    • Randomized, double-blind, controlled data on the treatment of mania with Quetiapine
  • Martin Jones, AstraZeneca, Wilmington, United States
    • Quetiapine for the treatment of mania in bipolar disorder: A randomized controlled trial
  • Björn Paulsson, AstraZeneca, Clinical R&D Södertläje, Sweden
    • Quetiapine adjunctive therapy for acute mania associated with bipolar disorder
  • Jamie Mullen, AstraZeneca, Wilmington, United States
    • Lithium therapy in treatment-resistant catatonia
  • Joseph W Y Lee, Graylands Hospital, Australia
    • Olanzapine/Fluoxetine combination in the treatment of rapid-cycling bipolar depression
  • Dr Sara A Corya, Lilly Research Laboratories, Indianapolis, United States
    • Analysis of treatment-emergent mania with Olanzapine/Fluoxetine combination
  • Dr Sara A Corya, Lilly Research Laboratories, Indianapolis, United States
    • Open-label maintenance treatment for bipolar depression using Olanzapine or Olanzapine/Fluoxetine combination
  • Dr Sara A Corya, Lilly Research Laboratories, Indianapolis, United States
    • Olanzapine’s efficacy for relapse prevention in bipolar disorder: A randomized double-blind placebo-controlled 12-month clinical trial
  • Dr Mauricio Tohen, Lilly Research Laboratories, United States
    • Olanzapine versus lithium in relapse prevention in bipolar disorder: A randomized double-blind controlled 12-month clinical trial
  • Dr Mauricio Tohen, Lilly Research Laboratories, Indianapolis, United States
    • Olanzapine versus placebo in the prevention of relapse for mixed index versus manic index episode patients
  • Dr Mauricio Tohen, Lilly Research Laboratories, Indianapolis, United States
    • Olanzapine/Fluoxetine combination for treatment-resistant depression with current SSRI failure
  • Dr Sara A Corya, Lilly Research Laboratories, Indianapolis, United States
    • Effects of lamotrigine on neurocognitive measures in bipolar I patients
  • Dr Lakshmi N Yatham, University of British Columbia, Vancouver, Canada
    • Effects of lamotrigine on quality of life in patients with bipolar I disorder
  • Anupama A Krishnan, GlaxoSmithKline, United States
  • Dr Gary Evoniuk, GlaxoSmithKline, United States
    • Levetiracetam in the treatment of acute mania: An open pilot study
  • Heinz Grunze, LMU Munich, Germany
    • Efficacy and Safety of Aripiprazole in Acute Mania: Results from a Second Placebo-Controlled Study
  • Elizabeth Hale, Bristol-Myers Squibb Company, Australia
    • Low doses of sodium valproate reduce melatonin light sensitivity in healthy volunteers
  • Karen T Hallam, University of Melbourne, Austin Health, Australia
    • Low doses of lithium carbonate reduce melatonin light sensitivity in healthy volunteers
  • Karen T Hallam, University of Melbourne, Austin Health, Australia
    • Melatonin sensitivity to white light in monozygotic twins discordant for bipolar I disorder
  • Karen T Hallam, University of Melbourne, Austin Health, Australia